These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 33843947)
21. Pregnant Patients Using Opioids: Treatment Access Barriers in the Age of COVID-19. Lensch AC; Hairston E; Carter G; Jones HE J Addict Med; 2022 Jan-Feb 01; 16(1):e44-e47. PubMed ID: 33606424 [TBL] [Abstract][Full Text] [Related]
22. Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID-19 pandemic. Rosansky JA; Albanese M; Phillips J; Schuman-Olivier Z Am J Addict; 2023 Nov; 32(6):615-618. PubMed ID: 37543849 [TBL] [Abstract][Full Text] [Related]
23. The Opioid Epidemic During the COVID-19 Pandemic. Haley DF; Saitz R JAMA; 2020 Oct; 324(16):1615-1617. PubMed ID: 32945831 [No Abstract] [Full Text] [Related]
24. Methadone and buprenorphine treatments in patients with schizophrenia. Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511 [No Abstract] [Full Text] [Related]
25. Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. Spetz J; Hailer L; Gay C; Tierney M; Schmidt L; Phoenix B; Chapman S JAMA Netw Open; 2022 May; 5(5):e225996. PubMed ID: 35552728 [TBL] [Abstract][Full Text] [Related]
26. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic. Narayan A; Balkrishnan R Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. Fishman MJ; Wu LT; Woody GE Am J Psychiatry; 2011 Jul; 168(7):675-9. PubMed ID: 21724673 [No Abstract] [Full Text] [Related]
28. Addressing a dual public health emergency: supporting physicians to prescribe opioid medications. Bandara NA; Mehrnoush V; Herath J CMAJ; 2020 Nov; 192(44):E1369. PubMed ID: 33139427 [No Abstract] [Full Text] [Related]
29. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder. Wilson CG; Ramage M; Fagan EB J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732 [No Abstract] [Full Text] [Related]
30. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847 [TBL] [Abstract][Full Text] [Related]
31. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447 [TBL] [Abstract][Full Text] [Related]
32. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period. Lembke A; Ottestad E; Schmiesing C Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378 [No Abstract] [Full Text] [Related]
33. Opioid use and misuse in Europe: COVID-19 new challenges? Torrens M; Fonseca F Eur Neuropsychopharmacol; 2022 Jan; 54():67-69. PubMed ID: 34565653 [No Abstract] [Full Text] [Related]
34. Tales from the frontlines: An alarming rise in hospitalizations related to opioid use disorder in the era of COVID-19. Ivey N; Clifton DC J Opioid Manag; 2021; 17(1):5-7. PubMed ID: 33735422 [TBL] [Abstract][Full Text] [Related]
35. Buprenorphine to treat opioid use disorder: A practical guide. Nissly T; Levy R J Fam Pract; 2018 Jun; 67(9):544-548. PubMed ID: 30216393 [TBL] [Abstract][Full Text] [Related]
36. Mortality Among Patients Prescribed Buprenorphine for Opioid Use Disorder After Disenrollment from an Insurance Plan and Healthcare System. Nguyen AP; Glanz JM; Shoup JA; Campbell CI; Clarke CL; Ford MA; Binswanger IA J Gen Intern Med; 2022 Aug; 37(11):2882-2884. PubMed ID: 35083649 [No Abstract] [Full Text] [Related]
37. Overcoming Barriers to Treatment of Opioid Use Disorder. Olsen Y; Fitzgerald RM; Wakeman SE JAMA; 2021 Mar; 325(12):1149-1150. PubMed ID: 33630021 [No Abstract] [Full Text] [Related]
38. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. Harris R; Rosecrans A; Zoltick M; Willman C; Saxton R; Cotterell M; Bell J; Blackwell I; Page KR Drug Alcohol Depend; 2022 Jan; 230():109187. PubMed ID: 34890927 [TBL] [Abstract][Full Text] [Related]
39. Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment. Hickman M; Macleod J; Degenhardt L Addiction; 2016 Jan; 111(1):83-4. PubMed ID: 26669528 [No Abstract] [Full Text] [Related]
40. The Implementation of a Clinic-Based Opioid Review Board to Address High-Risk Opioid Prescribing in Primary Care. Robbins JL; Byler J; Vinti A; Watson S; Azar AS; Korthuis PT; Pickett M Ann Fam Med; 2021; 19(6):563. PubMed ID: 34750135 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]